Neurotrope nosedives on iffy Alzheimer's trial

The biotech tries to spin poor results in a trial of its Alzheimer's disease drug, but investors aren't buying it. 

By Suzanne Elvidge • May 2, 2017

Late-stage failure puts an end to Aeterna Zentaris' lead therapy

Zoptrex's miss caused the Canadian pharma's stock to plummet 60% on Monday.

By Jacob Bell • May 2, 2017

Explore the Trendline➔

Neuroscience drug development

Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

By BioPharma Dive staff

Stepping up the game: Measles, mumps, rubella, and varicella (MMRV) concomitant testing support for vaccine evaluation

New CRO testing spaces fill the need for high quality data generated using quantitative immune assays and PRNt testing calibrated to the WHO international standard. 

By Rolando Pajon, PhD, Vaccine Validation Scientist, Vaccine and Novel Immunotherapeutic Laboratory Solutions • May 2, 2017

Medeor gets FDA go-ahead for Phase 3

The biotech is developing an immunotherapy that could replace immunosuppressants for transplant patients should it be successful. 

By Suzanne Elvidge • May 1, 2017

Prescribed Reading: Rough start for pharma, but optimism abounds

First quarter earnings were not particularly strong, but there were several bright spots; Gottlieb confirmation rolls forward; and The Medicines Co. lays down cash for its CV outcomes trial.

By Lisa LaMotta • April 28, 2017

Jazz hits a high note with positive narcolepsy results

Jazz isn't tired of good news this month: following significant improvements in sleepiness and sleep apnea, the company trumpets positive narcolepsy data.

By Suzanne Elvidge • April 28, 2017

Bristol-Myers surprises with continued Opdivo growth

Despite setbacks in its clinical program, Bristol-Myers is still firmly committed to the lung cancer space and has laid out a broad program for its assets. 

By Lisa LaMotta • April 27, 2017

AstraZeneca still playing catch up in I/O

The British pharma is trying to hone its oncology strategy as it attempts to compete in what is becoming an increasingly crowded marketplace. 

By Suzanne Elvidge • April 27, 2017

Q1 Earnings Preview: AbbVie, AstraZeneca, BMS, Celgene, Roche, Sanofi

Immuno-oncology will be in the spotlight over the next few days as AstraZeneca, Bristol-Myers and Roche are set to present new details on their competing drugs.

By Ned Pagliarulo , Lisa LaMotta , Jacob Bell • April 26, 2017

Medicines Co. charts ambitious late-stage tests for heart drug

The biotech hopes to quickly catch Amgen and the team of Sanofi and Regeneron, who are battling each other to secure an advantage in the PCSK9 market.

By Ned Pagliarulo • April 26, 2017

Cancer immunotherapy works, but how to find which patients will benefit?

Bristol-Myers Squibb has paired up with Foundation Medicine to explore new ways of identifying patients most likely to respond to immuno-oncology drugs like Opdivo.

By Ned Pagliarulo • April 25, 2017

Cel-Sci withdraws 2016 study protocol amendment

Could this be the light at the end of the tunnel for Cel-Sci's Multikine development?

By Suzanne Elvidge • April 25, 2017

EASL: Bristol-Myers' drug cuts liver fat in NASH

The mid-stage NASH drug showed potential in lowering both liver fat and fibrosis levels in overweight patients.

By Suzanne Elvidge • April 24, 2017

Lilly's abemaciclib hits mark in MONARCH 3

The highly anticipated CDK 4/6 inhibitor significantly improved progression-free survival, according to an interim analysis.

By Jacob Bell • April 24, 2017

EASL: Experimental drug slashes fatty liver markers in Phase 2

NGM Bio comes out of stealth mode to trumpet positive NASH data at the International Liver Congress. 

By Suzanne Elvidge • April 22, 2017

Hep C combo clears virus at 12 weeks

AbbVie and Enanta's hep C combo shows 99% response at 12 weeks. But in this crowded market, does it really matter?

By Suzanne Elvidge • April 21, 2017

Prescribed Reading: What J&J says about the rest of pharma

J&J earnings predict a rough first quarter for big pharma, AbbVie has a bad week, and Lilly's surprise rejection is great news for Pfizer. 

By Lisa LaMotta • April 21, 2017

Building a lab when constrained by space

Kendall Square has become a thriving hotspot for biotech and pharma, but real estate is both expensive and limited. Accelerated Commercialization Spaces offer companies a cost-friendly alternative. 

By Seth Taylor • April 20, 2017

Biopharma opening up to new ways of partnering on R&D

A report from Deloitte found the number of early-stage, science-focused collaborations to have increased rapidly over the past 10 years. 

By Ned Pagliarulo • April 20, 2017

AbbVie's PARP inhibitor fails two late-stage cancer trials

Veliparib did not meet primary endpoints in studies testing it as a treatment for lung and breast cancer.

By Jacob Bell • April 20, 2017

Novartis CAR-T candidate clinches breakthrough designation

It's the second such designation for the immunotherapy, which is in a dead heat with Kite Pharma's drug to be first to market.

By Jacob Bell • April 19, 2017

Positive results help Ultragenyx recover after prior failure

The ultra rare disease biotech announced positive topline results for its mid-stage drug partnered with Japan's Kyowa Hakko Kirin Co.

By Lisa LaMotta • April 19, 2017

Mateon announces positive topline data in ovarian cancer

Results from a combination study in recurrent ovarian cancer provided an early glimmer of hope in hard-to-treat patients.

By Suzanne Elvidge • April 19, 2017

Deja vu for Circassia with second allergy failure

The British biotech once again blames a high placebo effect for the failure of one of its allergy immunotherapies. 

By Lisa LaMotta • April 18, 2017

Allergan, Novartis ink NASH partnership

The deal will pair Allergan's drug cenicriviroc and Novartis' candidate LJN452 in a Phase 2b study of patients with the liver disease.

By Jacob Bell • April 18, 2017